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Abstract
Introduction: Muscle stem cells termed satellite cells are essential for muscle regeneration. A central question in
many neuromuscular disorders is why satellite cells are unable to prevent progressive muscle wasting. We have
analyzed muscle fiber pathology and the satellite cell response in Pompe disease, a metabolic myopathy caused by
acid alpha-glucosidase deficiency and lysosomal glycogen accumulation. Pathology included muscle fiber
vacuolization, loss of cross striation, and immune cell infiltration.
Results: The total number of Pax7-positive satellite cells in muscle biopsies from infantile, childhood onset and
adult patients (with different ages and disease severities) were indistinguishable from controls, indicating that the
satellite cell pool is not exhausted in Pompe disease. Pax7/Ki67 double stainings showed low levels of satellite cell
proliferation similar to controls, while MyoD and Myogenin stainings showed undetectable satellite cell
differentiation. Muscle regenerative activity monitored with expression of embryonic Myosin Heavy Chain was weak
in the rapidly progressing classic infantile form and undetectable in the more slowly progressive childhood and
adult onset disease including in severely affected patients.
Conclusions: These results imply that ongoing muscle wasting in Pompe disease may be explained by insufficient
satellite cell activation and muscle regeneration. The preservation of the satellite cell pool may offer a venue for the
development of novel treatment strategies directed towards the activation of endogenous satellite cells.
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Introduction
Healthy skeletal muscle has a remarkable capacity to
repair both minor and severe damage. Extensive muscle
damage, such as caused by exercise or in muscular
disease, requires a stem cell-mediated response. The
muscle stem cells or muscle satellite cells are located at
the myofiber periphery underneath the basal lamina [1].
Satellite cells are normally quiescent, but become rapidly
activated after damage and proliferate to generate a large
set of progeny that is capable of regenerating damaged
myofibers by fusion. Recent elegant studies using mouse
models that allow conditional depletion of the muscle
stem cell pool showed that satellite cells are indispensible
for muscle regeneration [2–5].
Genetic diseases affecting skeletal muscle pose a con-
tinuous challenge to the muscle regenerative system.
More than 700 neuromuscular disorders are known [6].
While the molecular pathological processes behind the
muscle diseases are diverse, in all cases the balance be-
tween muscle injury and regeneration is disturbed
resulting in progression of muscle wasting. The central
question is why the muscle regenerative program is
incapable of efficiently repairing disease-induced muscle
damage.
One hypothesis to explain this is depletion of the satel-
lite cell pool due to continuous regeneration attempts.
This idea has been derived from in vitro characterization
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of myoblasts from Duchenne Muscular Dystrophy
(DMD) patients, which showed reduced proliferative
capacity [7]. In agreement, studies using a mouse model
for DMD (termed mdx) suggested the existence of a
subpopulation of satellite cells that is exhausted in mdx
mice [8]. However, electron microscopy and immuno-
fluorescent analysis of skeletal muscle biopsies have
shown that the number of satellite cells can be increased
rather than exhausted in muscular dystrophies (includ-
ing DMD, myotonic dystrophy, Limb Girdle Muscular
Dystrophy type 2A (LGMD2A)) and inflammatory my-
opathies (including polymyositis, sporadic inclusion
body myositis, and dermatomyositis) [9–13]. Besides in-
creased proliferation, also increased satellite cell differ-
entiation was observed in the above diseases as indicated
by increased expression of myogenic lineage (MyoD,
Myogenin) and muscle regenerative (embryonic Myosin
Heavy Chain (eMyHC)) markers. The chronic satellite
cell activation and inflammation may result in Trans-
forming Growth Factor (TGF-β) signaling-mediated fi-
brosis at the cost of muscle repair [14].
A different group of neuromuscular disorders are the
metabolic myopathies [6]. Recent findings suggest that
metabolic changes can affect satellite cell function and
skeletal muscle regeneration [15]. Here we have investi-
gated the muscle regenerative response in Pompe disease
(OMIM 232300). Pompe disease is caused by acid-alpha
glucosidase (GAA) deficiency resulting in lysosomal glyco-
gen accumulation in a variety of tissues, but its effect is
most damaging in skeletal muscle (reviewed in [16]). The
clinical spectrum of Pompe disease ranges from severely
affected infants (the classic infantile form) to children and
adults with a slower progressive form of Pompe disease
(the non-classic or late onset form) [17–21]. The muscle
pathology in Pompe disease is distinct from that in mus-
cular dystrophies as fibrosis is not a prominent feature
and immune responses are considered to be low. The
pathological changes in skeletal muscle of Pompe patients
are progressive and range from enlarged lysosomes in
between myofibrils to completely vacuolized myofibers.
We have analyzed skeletal muscle biopsies from classic
infantile patients and from patients with childhood and
adult onset Pompe disease and compared the extent of
muscle damage, satellite cell activation, immune cell
infiltration, and muscle regenerative activity.
Materials and methods
Patients and control biopsies
Muscle biopsies were taken from the Vastus Lateralis
using a standard open surgery or needle biopsy proced-
ure as described previously [22] from Pompe patients,
two DMD patients and control subjects. Control sub-
jects were selected for which a progressive neuromuscu-
lar disorder was ruled out by medical history and muscle
tissue sections showed normal histology on haematoxy-
lin and eosin staining. The Ethical Committee of the
Erasmus MC University Medical Center approved the
use of the biopsies (MEC 2007–103). Written informed
consent was obtained from all patients and control sub-
jects or their legal guardians. All samples were frozen in
N2-chilled isopentane and cryosectioned (5–10 μm).
Medical Research Council (MRC) sumscores were calcu-
lated from the assessment of the strength of 26 muscle
groups essentially as described [23].
Histology
HE staining and Periodic Acid Schiff (PAS) staining were
performed on tissue that was processed into glycolmeta-
crylate (GMA) [24]. Acid Phosphatase (AP) staining was
performed on cryosections [25].
Scoring of muscle damage
Scoring of muscle damage was based on a system previ-
ously described by [22]. All sections were evaluated by
two researchers (RV, GS), who were blinded to the iden-
tity and clinical details of the patients. The level of dis-
turbance of cross striation and vacuole density as
discernable by light microscopy and PAS-staining inten-
sity was determined for sections of each patient on a
scale from 0–3. The scale for each category is provided
in Table 1. The number of damaged fibers was expressed
as percentage of total number of fibers present in the
section. The overall muscle damage score was expressed
as the sum score of cross striation, vacuole density and
PAS intensity.
Immunohistochemistry
5–10 μm cryosections of patient and control biopsies
were stored until analysis at −80 °C. Sections were
thawed before staining. Primary antibodies were directed
against CD68, clone KP1 (M0814; DAKO; 1:800),
eMyHC (F1.652; DSHB; 1:150), Ki67 (Ab15580; Abcam;
1:50), Laminin (L9393; Sigma; 1:500 or LS-C96142; LS
Bio; 1:500), MyoD (SC304; Santa Cruz; 1:200), Myogenin
(M-225 ; Santa Cruz; 1:200), Pax7 (DSHB; 1:50), CD3
(2GV6; Ventana; ready to use), CD20Cy; clone L26;
Dako, 1:400). Following the primary antibody incubation,
sections were rinsed and incubated with biotin-conjugated
anti-mouse antibody (BA-2000; Vector labs,1:50) and then
with Alexafluor594-conjugated streptavidin (S11227; Life
Technologies, 1:500). Sections incubated with rabbit
primary antibodies were subsequently incubated with
Alexafluor 488-conjugated goat-anti rabbit antibodies
(A11307; Life Technologies,1:500). Finally chicken anti-
Laminin was detected with Alexafluor647-conjugated goat
anti-chicken antibodies (A21449; Life Technologies, 1:500).
All sections were counterstained with Hoechst33258
(H3569; Life Technologies, 1:15000). The slides were
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mounted with Mowiol (475904; Calbiochem). For some bi-
opsies, limited amounts of sections of sufficient quality
were available for immunofluorescent analysis, and not all
stainings could be performed for all patients.
Image acquisition and analysis
For digital imaging complete histological sections were
scanned on a Hamamatsu NanoZoomer 2.0 (Hamamatsu
Photonics). Images were analyzed using NDP view soft-
ware (NDP View 1.2.31 ENG, Hamamatsu Photonics).
Sections for immunofluorescence were scanned on a Zeiss
LSM700 (Carl Zeiss B. V., Sliedrecht, The Netherlands)
using tile-scan modality. Image analysis was performed
using Fiji (fiji.sc/Fiji).
Statistical analysis
All data are expressed as means ± SD. Multiple groups
were compared using a one way non-parametric ANOVA.
Bonferroni correction was applied as Post-hoc test to ad-
just for multiple testing. Statistical significance was set at
P <0.05. All calculations were performed using Graphpad
5.0 (Graphpad software, USA).
Results
Study design and skeletal muscle pathology
Biopsies of Pompe patients before the start of enzyme
replacement therapy were taken from the Quadriceps
Femoris (QF) and were used in this study. Patients were
categorized into 4 groups based on age of disease onset
and disease severity: (1) Classic infantile Pompe disease,
with disease onset shortly after birth; (2) Childhood on-
set Pompe disease—disease onset ranging from 1 to
18 years; (3) Adult Pompe disease—mildly affected
(>18 years old and <15 years disease symptoms); (4)
Adult Pompe disease—severely affected (>18 years old
and >15 years disease symptoms and requirement of
walking aids and/or ventilator). Mildly affected adults
(group 3) on average appeared younger as compared to
severely affected adults (group 4) (Additional file 1:
Table S1), although this was not significant. MRC sum-
scores were the lowest in the severely affected adult onset
patient group, while these were higher in the childhood
and mildly affected adult onset groups (Additional file 2:
Figure S1). Histopathological findings are shown in Fig. 1a
and quantified in Fig. 1b. HE staining was used to assess
muscle damage, vacuolization, and cross striation. Dam-
aged muscle, characterized by irregular shaped fibers and
spaces in between the fibers were observed in all groups.
This was also the case for loss of cross striation. Vacuoli-
zation, caused by extensive lysosomal pathology and
muscle degeneration [26] was most extreme in biopsies
from classic infantile patients and the least in mildly af-
fected adults. PAS and acid phosphatase stainings were
used to further evaluate enlarged lysosomes. Both stain-
ings showed clear abnormalities for all patients examined.
Classic infantile patients exhibited the most extensive PAS
and acid phosphatase staining that was either localized or
present throughout the entire muscle fiber. Similar but
less severe staining was seen in the adult severely affected
patients. Childhood onset and mildly affected adult pa-
tients lacked staining throughout the entire fibers but
showed localized PAS- and acid phosphatase- positive
areas. In GMA-fixed sections, no gross disruption of the
sarcolemma was observed even in classic infantile pa-
tients. An overall scoring for muscle damage was per-
formed based on the abnormalities described above
(Fig. 1c). This shows an order of severity (from severe to
less severe) of classic infantile (group 1), severely affected
adults (group 4), childhood onset (group 2), and mildly
affected adults (group 3).
The satellite cell pool remains intact during
disease progression
Studies in rodents have shown that muscle repair is
completely dependent on muscle satellite cells [2–4].
This raised the question how satellite cells respond to
muscle pathology in Pompe disease. To determine
whether the number of satellite cells is altered, satellite
cells were identified and quantified in muscle biopsies
using two criteria: positive nuclear staining for Pax7, a
universal and sensitive marker of satellite cells [27, 28],
and the characteristic location under the basal lamina
(Fig. 2a). Quantification was performed by counting the
number of satellite cells per surface area (Fig. 2b) and
per total amount of nuclei (Fig. 2c). Representative stain-
ings for patient groups and controls are presented in
Fig. 2d. Both control and Pompe biopsies showed simi-
larly high numbers of satellite cells at early ages of 1–2
Table 1 Scoring of muscle damage based on pathology in muscle fibers
Score Cross striation PAS-positive staining Vacuoles
0 Normal None None
1 >75 % normal Little in most and/or all Little in all and/or significant in some
2 25–75 % normal Significant in all and strong in some;
significant and/or strong in most
Significant in all and/or many in some
3 <25 % normal Very strong in all Many in all
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Fig. 1 (See legend on next page.)
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years. Satellite cell numbers then decreased with age in
both controls and Pompe patients without obvious differ-
ences. Two DMD patients of 5 and 8 years of age also
showed normal satellite cell numbers. This indicated that
despite severe disease progression, Pompe patients retain
normal satellite numbers in the Quadriceps Femoris.
Immune response
Myofiber necrosis is known to induce a rapid and transi-
ent activation of the innate immune system [29], which
is essential for successful completion of muscle regener-
ation. Macrophages, both resident and recruited to dam-
aged muscle, play diverse and critical roles in muscle
regeneration in clearing necrotic debris and producing
mitogens that drive satellite cell proliferation [30]. In
neuromuscular disease, the ongoing muscle wasting
process can affect the immune response with various
outcomes. For example, a chronic immune response is
thought to contribute to the development of muscle fi-
brosis in DMD [31]. To determine whether macrophages
infiltrate skeletal muscle in Pompe disease, sections were
stained for the pan-macrophage marker CD68. This
showed the presence of CD68-positive cells in between
muscle fibers (Fig. 3a, white arrows) and occasionally in-
side necrotic fibers (Fig. 3a, yellow arrowhead) from a
severely affected adult onset patient which were absent
in a control patient (Fig. 3a). Fig. 3b shows a detail of a
biopsy from a severely affected patient with a necrotic
fiber surrounded by and containing CD68-positive cells,
suggesting active phagocytosis. In a GMA-fixed HE
stained section of a biopsy from a mildly affected patient
that showed substantial pathology, degenerating fibers
with multiple macrophage-like nuclei inside the fiber,
characteristic of early-stage necrosis, were identified,
supporting the idea of phagocytosis (Fig. 3c). Biopsies
with milder muscle fiber pathology did not show evi-
dence of phagocytosis or elevated CD68 expression (data
not shown). Adult patients with severe muscle pathology
showed low numbers of end-stage necrotic fibers (<1 %
of total fibers), whereas variable numbers of degenerat-
ing fibers with cell infiltration were observed ranging
from 5 to 30 % of total fibers. The disrupted morphology
of biopsies from classic infantile patients did not allow
an analysis of CD68-positive cells around muscle fibers,
however, numerous CD68-positive cells were observed
(data not shown). No gross infiltration with CD20-
positive B and CD3-positive T lymphocytes were
detected in any patient group (<1–2 per section). These
findings suggest that necrotic muscle fibers in Pompe
patients are subject to macrophage-mediated phagocyt-
osis in severely affected muscle biopsies. The repair of
such damage is expected to require a satellite cell-
mediated regenerative response.
Compromised activation of satellite cells
The first step in activation of satellite cells, which are
normally quiescent, involves cell proliferation. This re-
sult in temporary expansion of the satellite cell pool
followed by differentiation to myoblasts. Triggers for ac-
tivation include injury induced by exercise or disease. To
determine to what extent satellite cells are activated in
Pompe disease, biopsies were co-stained for Pax7 and
Ki67, a marker of cell proliferation that is expressed dur-
ing all phases of the active cell cycle but is absent in qui-
escent cells (Fig. 4a and Additional file 3: Figure S2).
Ki67-positive satellite cells were detected in all four
Pompe patient groups and varied from 2 to 12 % of the
total Pax7-positive satellite cells (Fig. 4b), whereas the
percentage of Ki67-positive nuclei was on average ~1 %
(Additional file 4: Figure S3). Control biopsies showed a
similar range of Ki67-positive satellite cells and Ki67-
positive nuclei from infantiles to adults. The absolute
numbers of Pax7/Ki67 double positive cells were low
due to the low numbers of the satellite cells themselves
hampering accurate quantification. Satellite cell activa-
tion by differentiation into the myogenic lineage was ex-
amined using stainings of MyoD and Myogenin. While
MyoD and Myogenin-positive satellite cells could be de-
tected in human (Additional file 5: Figure S4) and mouse
(data not shown) muscle biopsies, their frequency was
too low in all patient groups and controls (0–1 per bi-
opsy) to allow quantitative analysis. Taken together,
satellite cells in Pompe disease show low levels of activa-
tion that are indistinguishable from controls, and no
disease-induced satellite cell response was observed.
Muscle regeneration
The lack of satellite cell activation predicted that muscle
regenerative activity is low in Pompe disease. To test this,
eMyHC stainings were performed. eMyHC is expressed
during normal muscle development in the embryo as well
as transiently during active muscle repair postnatally [32].
eMyHC expression in postnatal skeletal muscle is a strong
indicator of an active regeneration response. Biopsies from
(See figure on previous page.)
Fig. 1 Skeletal muscle pathology of Pompe patients. Patients were divided in four groups as indicated based on disease onset and severity.
a Representative examples of each group with HE (GMA), PAS (GMA), and acid phosphatase (frozen section) stainings of biopsies from the QF.
b Biopsies were scored for vacuole density, % damaged fibers, PAS intensity, and % loss of cross striation for each patient group. Data are means
+/− SD of three patients per group. c Scores of (b) were combined in an overall score for muscle damage. Group 1 n = 3, group 2 n = 2, group 3
n = 4, group 4 n = 5. Data are means +/− SD *: p < 0.05; **: p < 0.01. AU: arbitrary units
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classic infantile patients showed weak (Fig. 5, left sections)
to no detectable eMyHC (Fig. 5, right section) staining.
eMyHC staining was undetectable in all childhood onset,
mildly affected adult onset, and severely affected adult on-
set Pompe patients examined as well as in control biopsies
(Fig. 5). In contrast, eMyHC was strongly expressed in
DMD patients (Fig. 5). This underscored the absence of
a robust muscle regenerative response in Pompe dis-
ease. However, GMA-fixed HE stained biopsies from
the most severely affected adult patients showed some
fibers with an array of centrally located nuclei inside
muscle fibers (Additional file 6: Figure S5), suggesting
that a weak regenerative response is present in
strongly affected muscles.
Fig. 2 Satellite cell numbers remain unchanged and are independent of Pompe disease severity. a Identification of satellite cells (white arrows)
by immunofluorescent analysis of Pax7 in human skeletal muscle biopsies. Upper left: Pax7; upper right: Hoechst; lower left: Laminin; lower right:
merge. b, c Quantification of Pax7-positive cells in all Pompe biopsies examined in this study. Healthy control biopsies are included, as well as
biopsies from two DMD patients. b Number of satellite cells (SCs)/mm2. c Percentage of SCs/nuclei. d Representative examples of each Pompe
patient group, age-matched controls, and a DMD patient. Pompe patients: group 1 n = 3, group 2 n = 4, group 3 n = 4, group 4 n = 3. DMD
patients: n = 2. Controls: infants n = 2, juveniles n = 2 and adult n = 5. For both Fig. 2b and c: Group 1 Pompe patients were statistically significant
from other Pompe patient groups (p < 0.0001). Control infants were statistically significant from other controls (p < 0.0001). Other comparisons
were not significantly different
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Discussion
Satellite cell numbers are neither increased nor
exhausted in Pompe disease
We have shown that the numbers of satellite cells in
skeletal muscle biopsies from Pompe patients are similar
to controls. The number of satellite cells is known to be
age-dependent with a ratio of 12 % (satellite cells/myo-
nuclei) at 1–2 years of age, followed by a decline to
about 2 % in adults [33]. Pompe patients and controls
followed a similar age-dependent pattern. This finding is
surprising given the extensive muscle pathology, espe-
cially in classic infantile patients. These patients showed
strongly disrupted myofiber organization with loss of cross
striation, widespread glycogen accumulation, and numer-
ous vacuoles, as described previously [22, 26, 34, 35]. Dis-
tinct pathology was seen in muscle biopsies from clinically
severely affected adult patients and in some of the child-
hood onset patients. A priori, a satellite cell response to
Pompe disease was anticipated. Based on the level of
muscle damage, a possible scenario was exhaustion of the
satellite cell population as a result of continuous cycles of
regeneration, as has been proposed for DMD patients.
Another scenario would be an increase in satellite cell
numbers due to satellite cell activation resulting in
increased proliferation, as seen in a number of neuromus-
cular disorders including dystrophies and inflammatory
myopathies [9–13]. These possible scenarios are not ne-
cessary mutually exclusive and may be dependent on the
disease severity and age at which the satellite status is ex-
amined. Here, we analyzed the satellite cell response for
Pompe patients with various degrees of disease severity
and different ages in order to cover these possible scenar-
ios. This showed that during all disease stages including in
classic infantile patients and in severely affected adult pa-
tients at advanced age (around 70 years), the satellite cell
population remained intact, arguing against satellite cell
exhaustion in Pompe disease.
Impaired activation of satellite cells in Pompe patients
Both satellite cell proliferation, monitored from the per-
centage of Ki67-positive satellite cells, and differentiation,
indicated by the number of MyoD- and Myogenin-
positive cells, were similar to controls for all Pompe pa-
tient groups. This indicated a failure of a robust satellite
cell response in Pompe disease irrespective of disease se-
verity. A previous report described low levels of satellite
cell activation in classic infantile Pompe patients moni-
tored 1 year after enzyme replacement therapy [34]. Two
Fig. 3 Macrophage infiltration in severely affected patients. a Immunofluorescent analysis of CD68 expression in biopsies from an adult control
(left) or a severely affected adult onset Pompe patient (right). White arrows point to CD68-positive cells located between fibers, yellow arrowhead
to CD68-positive cell invading a myofiber. b Detail of a necrotic fiber from the patient shown in Fig. 3a (white arrow) with CD68-positive cells
around and inside the fiber. c GMA-fixed HE stained biopsy from a mildly affected Pompe patient
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patients that showed a good histological response to en-
zyme replacement therapy showed the lowest activation
levels. It would be interesting to compare the effect of en-
zyme replacement therapy by comparing baseline and
treated samples in future studies.
An important question is whether the failure of satel-
lite cell activation in Pompe disease is caused by the ab-
sence of an activating signal or the presence of an
inhibitory factor. In muscle injury induced experimen-
tally or by exercise, sarcolemmal damage triggers satel-
lite cell activation by disturbing the niche of the satellite
cell in between the sarcolemma and basal lamina. In
Pompe disease, no gross disruption of the sarcolemma
can be observed even in classic infantile patients, as
shown using electron microscopy [26] and light micros-
copy (provided glutaraldehyde-based fixation of biop-
sies). This would argue for reduced presence of a
satellite cell-activating signal in Pompe disease. However
we cannot rule out more subtle damage to the sarco-
lemma that has not been detected using these methods.
Subsequent signals involved in both activation and in-
hibition of muscle regeneration are derived from the im-
mune system. Following injury, a transient immune
response triggers satellite cell activation and muscle regen-
eration. However, chronic immune responses can potently
inhibit muscle regeneration and induce TGFβ-signaling-
mediated muscle fibrosis as is the case for the muscular
dystrophies. An immune response in Pompe patients is a
hereto understudied factor considering the paucity of pub-
lished reports on this aspect. One previous report has also
detected inflammatory cells in skeletal muscle of an adult
Pompe patient [36], but the cells have not been further
characterized. At the molecular level, microarray analysis
of genome wide mRNA expression patterns indicate ele-
vated expression levels of several genes involved in im-
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Fig. 4 Unchanged satellite cell proliferation in Pompe disease. a Example of a proliferating (arrow) and a quiescent (arrowhead) satellite cell in a
Pompe muscle biopsy. Cryosections were co-stained for Pax7 (red) to mark satellite cells and Ki67 (green) using immunofluorescence to assess
active proliferation. Nuclei were stained with Hoechst (blue). White arrow indicates an activated satellite cell. The yellow arrowhead indicates a
quiescent satellite cell. b Quantification of Ki67-positive satellite cells in Pompe patients (red symbols; different symbols per patient group),
controls (green symbols), and a DMD patient (blue symbol). Pompe patients: group 1 n = 3, group 2 n = 3, group 3 n = 4, group 4 n = 3. DMD
patient: n = 1. Controls: infants n =1, juveniles n = 2 and adults n = 5. There was no statistical difference between groups. The power to detect
differences in Ki67-positive satellite cells was 0.8 (sample size 3, alpha 5 %, 2-sided equality, SD 5 %, delta 24). Delta of 24 is based on a previous report
describing an increase of proliferating/activated satellite cells from ~0.5 % in healthy muscle to about 12 % after light resistance training [48]
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infantile patients [37]. In the current study, infiltration of
skeletal muscle with CD68-positive cells was observed in
severely affected Pompe patients and suggested the pres-
ence of macrophages involved in phagocytosis of degener-
ating muscle fibers. It remains to be determined how these
macrophages affect satellite cell activation or inhibition,
and to what extent glycogen accumulation in macrophages
from Pompe patients [38, 39] plays a role in this process.
Another factor that may contribute to the deregulation
of satellite cell activation is impaired autophagy. It has
been suggested that hematopoietic stem cells depend on
autophagy as energy source for proper activation [40], and
recent results also indicate a similar role for autophagy in
satellite cell activation [15]. Interestingly, autophagy in
skeletal muscle is impaired in Pompe disease [41, 42], war-
ranting further investigation on its role in modulating
satellite cell activation.
A venue for the development of novel treatment
strategies
The positive news for Pompe patients is that their satel-
lite cell pool is intact and not exhausted. This may open
novel treatment options targeted at enhancement of sat-
ellite cell activation and improved muscle regeneration.
Fig. 5 Impaired muscle regeneration in Pompe patients. Immunofluorescent analysis of embryonic myosin heavy chain (eMyHC in red)
expression in to detect actively regenerating myofibers. Muscle sections were co-stained for Laminin (in green) to visualize the fiber outline, nuclei
were stained with Hoechst (in blue). Representative examples are shown. Two examples from classic infantile Pompe patients and DMD patients
are derived from different patients
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A prerequisite for successful implementation of such an
approach is that the intrinsic properties of satellite cells
in Pompe patients are intact. Electron microscopy stud-
ies of satellite cells from Pompe patients showed normal
morphology [26]. Studies focused on the functional
characteristics of satellite cells in muscle of Pompe pa-
tients are required to fully address this subject. Several
factors have been shown to be capable of enhancing sat-
ellite cell activation, including growth factors, small mol-
ecules that modulate signaling pathways, immune
modulation, and physical exercise. In recent studies we
and others have shown that controlled exercise is well
tolerated by Pompe patients [43–47].
Conclusions
In conclusion, despite the extensive muscle damage sat-
ellite cells do not become robustly activated during
Pompe disease progression. In line with this, the regen-
erative response in skeletal muscle of classic infantile
Pompe patients was weak and absent in childhood- and
adult-onset Pompe patients. The preservation of the sat-
ellite cell pool may offer a venue for the development of
novel treatment strategies directed towards the activa-
tion of endogenous satellite cells.
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